Next Article in Journal / Special Issue
Where Do Bone-Targeted Agents RANK in Breast Cancer Treatment?
Previous Article in Journal
Short Term Culture of Human Mesenchymal Stem Cells with Commercial Osteoconductive Carriers Provides Unique Insights into Biocompatibility
J. Clin. Med. 2013, 2(3), 67-88; doi:10.3390/jcm2030067
Review

Bone-Targeted Agents for the Management of Breast Cancer Patients with Bone Metastases

1
, 2
, 1
, 3
, 1
 and 1,*
Received: 24 June 2013; in revised form: 25 July 2013 / Accepted: 29 July 2013 / Published: 19 August 2013
(This article belongs to the Special Issue Prevention and Treatment of Bone Metastases from Breast Cancer)
View Full-Text   |   Download PDF [239 KB, updated 21 August 2013; original version uploaded 19 August 2013]
Abstract: Despite advances in adjuvant therapy for breast cancer, bone remains the most common site of recurrence. The goal of therapy for these patients is palliative and focused on maximizing the duration and quality of their life, while concurrently minimizing any disease or treatment-related complications. Bone metastases predispose patients to reduced survival, pain, impaired quality of life and the development of skeletal-related events. With an increased understanding of the pathophysiology of bone metastasis, effective treatments for their management have evolved and are now in widespread clinical use. This article will discuss the pathogenesis of bone metastases and review the key clinical evidence for the efficacy and safety of currently available systemic bone-targeted therapies in breast cancer patients with an emphasis on bisphosphonates and the receptor activator of nuclear factor kappa B ligand (RANKL) inhibitors. We will also discuss novel strategies and therapies currently in development.
Keywords: bone metastases; bone-targeted therapy; skeletal-related events; bisphosphonates; denosumab bone metastases; bone-targeted therapy; skeletal-related events; bisphosphonates; denosumab
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Simos, D.; Addison, C.L.; Kuchuk, I.; Hutton, B.; Mazzarello, S.; Clemons, M. Bone-Targeted Agents for the Management of Breast Cancer Patients with Bone Metastases. J. Clin. Med. 2013, 2, 67-88.

AMA Style

Simos D, Addison CL, Kuchuk I, Hutton B, Mazzarello S, Clemons M. Bone-Targeted Agents for the Management of Breast Cancer Patients with Bone Metastases. Journal of Clinical Medicine. 2013; 2(3):67-88.

Chicago/Turabian Style

Simos, Demetrios; Addison, Christina L.; Kuchuk, Iryna; Hutton, Brian; Mazzarello, Sasha; Clemons, Mark. 2013. "Bone-Targeted Agents for the Management of Breast Cancer Patients with Bone Metastases." J. Clin. Med. 2, no. 3: 67-88.


J. Clin. Med. EISSN 2077-0383 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert